Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The scene of the antibody drug conjugate (ADC) market is unpredictably molded by a huge number of impacting factors. Relating to this particular area of the drug business, partners craving to gain by the valuable open doors should have a nuanced cognizance of these market factors.
Accuracy Medication and Designated Disease Treatments: The rising spotlight on designated malignant growth treatments and accuracy medication has considerably moved the ADC market. The nonstop movement of information in regard to disease science expands the requirement for treatment choices that are both exact and strong. ADCs, by prudence of their ability to regulate cytotoxic mixtures explicitly to malignant growth cells, are as per the precepts of accuracy medication.
Mechanical Progressions in Counter acting agent Designing: The ADC market is fundamentally affected by innovative advances in neutralizer designing. Progressions in payload conveyance frameworks, neutralizer plan, and formation strategies expand the particularity and adequacy of ADCs. Associations that designate assets towards state-of-the-art innovations accomplish an upper hand by creating prevalent items that address the consistently changing requests of the restorative business.
Oncology Medication Improvement Scene: The ADC market is significantly influenced by the more extensive scene of oncology drug advancement. The interest in ADCs is affected by the pervasiveness of specific disease types, the advancement of novel biomarkers, and the development of treatment standards. Organizations that better adjust their item improvement systems to the consistently changing oncology climate have a more prominent possibility of making progress.
Administrative Climate and Endorsements: The ADC market is fundamentally impacted by the administrative climate, explicitly the endorsement processes for novel therapeutics. Albeit thorough administrative norms ensure the security and viability of an item, they likewise present impediments as time and assets expected to enter the market. Associations that have the capacity to really explore administrative cycles can speed up the endorsement of their items, in this manner achieving an upper hand.
The ADC market is set apart by an exceptionally serious climate, which requires the execution of separation techniques. Associations that give particular ADC details, upgraded linker advances, or further developed security profiles separate themselves. As well as drawing in medical care experts, compelling separation impacts recommending designs, which adds to the development of piece of the pie.
The openness and reasonableness of ADC treatments for patients is a basic perspective that is influenced by different elements, including repayment strategies and the ability to pay. Associations whose evaluating methodologies work out some kind of harmony among maintainability and availability advance their market situating. Accomplishing broad patient access through medical services framework route is crucial for long haul market achievement.
Clinical Preliminary Outcomes and Genuine Proof: The validity and agreeableness of ADCs are impacted by the results of clinical preliminaries and the age of certifiable proof. Associations that allot assets towards complete clinical preliminary drives and reliably track experimental information can outfit medical care experts with convincing validation in regard to the adequacy and security of their items, consequently strengthening market trust.
Encouraging joint efforts and venturing into global business sectors are basic key targets for associations working in the ADC area. Possibilities for development are given by the cooperation of global accomplices and the variety of territorial medical care conditions. Associations that successfully oversee mind boggling worldwide administrative scenes and develop productive coalitions lay out an establishment for an extended market impression.
Patient and Doctor Training Drives: The ADC market is altogether affected by instructive drives that target the two patients and doctors. Associations that effectively partake in instructive missions improve public awareness as well as enable medical care specialists and patients to settle on very much educated choices. Upgrading cognizance helpfully affects market interest.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Market Size Value In 2022 | USD 2.31 Billion |
| Growth Rate | 16.70% (2022-2030) |
Antibody Drug Conjugate Market Highlights:
Global Antibody Drug Conjugate Market Overview
The antibody drug conjugate market size was valued at USD 1.98 billion in 2021 and is projected to grow from USD 2.31 Billion in 2022 to USD 6.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.70% during the forecast period (2022 - 2030). Growing Research and Development Activities for the Development of Novel Therapeutics and rising Incidence of Cancer are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Antibody Drug Conjugate Market Trends
- Growing Research and Development Activities to boost market growth
The rising incidence of cancer, the growing elderly population, and the rising R&D activities for the discovery of novel treatments are also significant drivers of the market expansion for antibody drug conjugate. The ability to use the precision of monoclonal antibodies toward specific antigens for the delivery of potential cytotoxic medicines, with increased activity and less toxicity as compared to chemotherapies, makes ADCs one of the fastest-growing treatments for cancer patients. In order to deliver highly potential cytotoxic drug molecules to the precise tumor-related antigens for cancer treatment, ADCs use antibodies as a carrier. The approval of 10 ADCs, include Adcetris and Kadcyla that target the Cd30 and HER2 antigen sites, respectively, is evidence of recent developments in ADC technology.
The market CAGR for antibody drug conjugate is anticipated to experience profitable expansion as research and development activities increase. For instance, at the 62nd annual meeting of the American Society of Hematology 2020 on December 7, 2020, ADC Therapeutics SA, a late-stage biotechnology company with an oncology focus, introduced the most recent clinical data of its two major initiatives, Loncastuximab-Tesirine (Lonca) and Camidanlumab-Tesirine (Cami). An antibody-drug conjugate (ADC) called loncastuximab tesirine is made up of a human monoclonal antibody that targets the human Cluster of Differentiation (CD)19 and is linked to a pyrrolobenzodiazepine (PBD) dimeric cytotoxin. The pyrrolobenzodiazepine (PBD) dimer payload tesirin is conjugated to a monoclonal antibody that binds to CD25 to create the antibody drug conjugate (ADC) known as camidanlumab Tesirin.
The Antibody Drug Conjugate market's growing investments are anticipated to strengthen the pipeline for antibody drug conjugate and expand its applications, both of which will contribute to the market's expansion. For instance, in 2022, Spirea Limited obtained GBP 2.4 million in fundraising with contributions from famous British and American investors. With these funding, the company will start developing its pipeline of better and distinctive ADCs for the treatment of solid tumors. Additionally, Mersana Therapeutics, Inc. and Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson, entered into a research cooperation and license agreement in February 2022 to find novel ADCs for three targets. Mersana will use its expertise, as well as its exclusive Dolasynthen platform, to identify fresh ADC product candidates. The studied market is therefore anticipated to increase significantly throughout the study period as a result of the factors mentioned. But during the course of the projected year, it's anticipated that the market growth would be restrained by strict governmental regulations, costly procedures, and a shortage of funds.
Antibody Drug Conjugate Market Segment Insights
Antibody Drug Conjugate Type Insights
The market segments of antibody drug conjugate, based on type, includes Monoclonal Antibodies, and Linker. The Monoclonal Antibodies segment held the majority share in 2021 contribution to around ~60-65% in respect to the antibody drug conjugate market revenue. This is primarily owing to the rising prevalence of various type cancer and growing demand of cost-efficient biosimilar monoclonal antibodies.
Figure 2: Antibody Drug Conjugate Market, by Type, 2021 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Antibody Drug Conjugate Applications Insights
The antibody drug conjugate market segmentation, based on applications, includes Leukemia, and Lymphoma. The Leukemia segment dominated the market in 2021. The rising incidence of leukaemia worldwide, which is anticipated to increase demand for treatments for the disease. ly, almost all forms of leukaemia, including ALL and CML, are becoming more common. For instance, the Leukemia & Lymphoma Society (LLS) released estimates estimating that in the US, leukaemia will be diagnosed in 60,530 million persons by the year 2020. Similar to this, the International Agency for Research on Cancer predicted that in 2020 there will be approximately 474,519 new cases of leukaemia worldwide. It is anticipated that a rise in patient populations ly will accelerate market growth.
Antibody Drug Conjugate Regional Insights
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America is predicted to hold dominant position in the worldwide market of antibody drug conjugate during the forecast period, due mainly to the launch of new products or approvals. For instance, on April 23, 2021, the next-generation oncology-focused biotechnology company ADC Therapeutics SA announced that ZYNLONTA (Loncastuximab Tesirinelpyl) has received FDA approval for the therapy of refractory or relapsed large B-cell lymphoma. Based on its overall response rate, the U.S. FDA granted fast approval to ZYNLONTA, an antibody-drug combination that target CD19.
Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: ANTIBODY DRUG CONJUGATE MARKET SHARE BY REGION 2021 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe antibody drug conjugate market accounts for the second-largest market share due to the advancement in the medical technology, obese population and rising ageing population in the region is anticipated to support the market’s growth during the forecast period. Further, the Germany market of antibody drug conjugate held the largest market share, and the UK market of antibody drug conjugate was the fastest growing market in the European region
The Asia-Pacific market of Antibody Drug Conjugate projected to grow at a CAGR of 18.7% during the forecast period. The approval of new antibody-drug conjugates in the area is responsible for the region's expansion. For instance, Japan's MHLW gave Astellas' enfortumab vedotin for therapy of metastatic or locally advanced urothelial cancer priority review in May 2021. Moreover, China market of antibody drug conjugate held the largest market share, and the India market of antibody drug conjugate was the fastest growing market in the Asia-Pacific region
Antibody Drug Conjugate Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market grow of antibody drug conjugate even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new research and development, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the antibody drug conjugate industry must offer cost-effective treatment and therapy to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the antibody drug conjugate industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, antibody drug conjugate industry has provided therapy with some of the most significant benefits. The antibody drug conjugate market major player such as ADC Therapeutics, Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., and others are working to expand the market demand by investing in research and development activities.
ADC Therapeutics a biotechnology company was established in 2011 and its headquarters is in Switzerland. ADC Therapeutics is a leader in the field of antibody-drug conjugates (ADCs). Its fully integrated value chain includes research, translational and biochemistry, manufacturing, and controls, all of which are specialised capabilities specific to the lifecycle of ADCs. Our extensive pipeline includes ADCs that are in clinical trials for cancers of the hematologic and solid human cancers. The company has a strong, tested technology foundation in highly effective PBD-based ADCs, and we are growing our reach to build assets of the next generation. In Nov. 2022, IGM Biosciences, Inc., a clinical-stage biotechnology company specialising in the development of IgM antibodies, and ADC Therapeutics SA recently announced that they have collaborated on a clinical trial and entered into a supply agreement to test the efficacy of imvotamab, a novel IgM CD20 x CD3 T cell engaging bispecific antibody from IGM, and ZYNLONTA® (loncastuximab tesirine-lpyl) (NHL).
Also, Seagen Inc. is an American biopharmaceutical company that focuses on creating and commercializing innovative, enabling monoclonal antibody-based treatments for treatment of cancer. The company was established in 1997 and its headquarters is in Bothell, Washington, United States. In March 2022, an exclusive collaboration agreement was signed by Sanofi and Seagen Inc. to create, develop, and market antibody-drug conjugates (ADCs) targeting up to three different cancer targets. The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen.
Key Companies in the antibody drug conjugate market includes
- ADC Therapeutics
- Takeda Pharmaceutical Company Ltd.
- GlaxoSmithKline Plc
- Hoffmann-La Roche Ltd.
- Daiichi Sankyo Company Ltd.
- Pfizer Inc.
- Seagen Inc.
- Gilead Sciences Inc.
- Astellas Pharma, among others
Antibody Drug Conjugate Industry Developments
February 2022:Eli Lilly and Company received exclusive rights from ImmunoGen Inc. to research, develop, and market antibody-drug conjugates (ADCs) that are directed at targets chosen by Lilly relying on ImmunoGen's novel camptothecin technology. This exclusive right was granted as part of a , multi-year definitive licence agreement.
September 2021:The FDA of the United States Administration granted STRO-002 to Sutro Biopharma, Inc. the Fast Track designation. It is an antibody-drug conjugate (ADC) that targets the folate receptor alpha (FolR) and is used to treat people with platinum-resistant epithelial ovarian, primary peritoneal cancer whom has received one to three lines of systemic therapy in the previous.
Antibody Drug Conjugate Market Segmentation:
Antibody Drug Conjugate Type Outlook
- Monoclonal Antibodies
- Linker
Antibody Drug Conjugate Product Outlook
- Adcertis
- Kadcyla
Antibody Drug Conjugate Technology Outlook
- Immunogen Technology
- Immunomedics Technology
Antibody Drug Conjugate Application Outlook
- Leukemia
- Lymphoma
Antibody Drug Conjugate End-User Outlook
- Biotechnology Companies
Antibody Drug Conjugate Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
